Grace Halsey

Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.

Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.

The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.

Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.

Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.

The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.

Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.

The overall CKD population will reach 125 million by 2032 across 8 industrialized nations, with significant clinical, social, economic, and environmental costs.

AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.

LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.

The AHS recommends the migraine-specific preventive medications be prescribed first, with no requirements to "fail" other treatments for eligibility.

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

New study findings raise important questions about how early to initiate therapy to reduce proteinuria and whether even lower levels should be sought to improve CKD outcomes.

ACC.24: Even modest alcohol intake increases risk for coronary heart disease in men and women but women are at much greater risk across levels of weekly consumption.

Resmetirom to treat NASH with F2-F3 fibrosis, the only approved therapy, is available through Madrigal's specialty pharmacy network, the company said.

The web app showed more than 90% concordance with clinical assessment of eligibility for low dose rosuvastatin; study yields 35.5% reduction in LDL-C.

Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.

ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.

ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.

ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.

ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.

In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.

More than 1 in 10 older adults were misdiagnosed with community-acquired pneumonia and nearly all were treated with a full course of antibiotics, a new study found.

Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.